- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
BridgeBio Oncology Therapeutics Inc (BBOT)
BridgeBio Oncology Therapeutics Inc stock price live, this page displays NASDAQ BBOT stock exchange data. View the BBOT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the BridgeBio Oncology Therapeutics Inc real time stock price chart below.
What Is the BridgeBio Oncology Therapeutics Inc Stock Price Today?
The BridgeBio Oncology Therapeutics Inc stock price today is 3.50.
What Is the Stock Symbol for BridgeBio Oncology Therapeutics Inc?
The stock symbol for BridgeBio Oncology Therapeutics Inc is "BBOT."
What Stock Exchange Does BridgeBio Oncology Therapeutics Inc Trade On?
BridgeBio Oncology Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is BridgeBio Oncology Therapeutics Inc a Good Stock to Buy?
Determining whether BridgeBio Oncology Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BBOT quote. (ISIN: US1079241022)
What Is the BridgeBio Oncology Therapeutics Inc Stock Price Today?
The BridgeBio Oncology Therapeutics Inc stock price today is 3.50.
What Is the Stock Symbol for BridgeBio Oncology Therapeutics Inc?
The stock symbol for BridgeBio Oncology Therapeutics Inc is "BBOT."
What Stock Exchange Does BridgeBio Oncology Therapeutics Inc Trade On?
BridgeBio Oncology Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is BridgeBio Oncology Therapeutics Inc a Good Stock to Buy?
Determining whether BridgeBio Oncology Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BBOT quote. (ISIN: US1079241022)
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.48
3.72
52 wk Range
3.48
14.87
Trading near 52-week Low
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.483.72
52 wk Range
3.4814.87
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BBOT Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
24.55
Upside
+601.30%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in oversold territory
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
12 Buy
0 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 24.55
(+601.30% Upside)
Earnings
Latest Release
Aug 11, 2026
EPS / Forecast
-705.20 / -0.52
Revenue / Forecast
-- / --
Compare BBOT to Peers and Sector
Metrics to compare | BBOT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBBOTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.6x | 12.9x | −0.3x | |
PEG Ratio | −0.02 | −0.52 | 0.00 | |
Price/Book | 0.9x | 5.3x | 2.6x | |
Price / LTM Sales | - | 4.2x | 3.0x | |
Upside (Analyst Target) | - | −3.0% | 58.5% | |
Fair Value Upside | Unlock | 23.3% | 7.1% | Unlock |
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the BridgeBio Oncology Therapeutics (BBOT) Stock Price Today?
The BridgeBio Oncology Therapeutics stock price today is 3.50 USD.
What Stock Exchange Does BridgeBio Oncology Therapeutics Trade On?
BridgeBio Oncology Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for BridgeBio Oncology Therapeutics?
The stock symbol for BridgeBio Oncology Therapeutics is "BBOT."
What Is the BridgeBio Oncology Therapeutics Market Cap?
As of today, BridgeBio Oncology Therapeutics market cap is 288.63M USD.
What Is BridgeBio Oncology Therapeutics's Earnings Per Share (TTM)?
The BridgeBio Oncology Therapeutics EPS (TTM) is -2.56.
When Is the Next BridgeBio Oncology Therapeutics Earnings Date?
BridgeBio Oncology Therapeutics will release its next earnings report on Nov 18, 2026.
From a Technical Analysis Perspective, Is BBOT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has BridgeBio Oncology Therapeutics Stock Split?
BridgeBio Oncology Therapeutics has split 0 times.
How Many Employees Does BridgeBio Oncology Therapeutics Have?
BridgeBio Oncology Therapeutics has 88 employees.
What is the current trading status of BridgeBio Oncology Therapeutics (BBOT)?
As of Oct 06, 2026, BridgeBio Oncology Therapeutics (BBOT) is trading at a price of 3.50 USD, with a previous close of 3.60 USD. The stock has fluctuated within a day range of 3.48 USD to 3.72 USD, while its 52-week range spans from 3.48 USD to 14.87 USD.
What Is BridgeBio Oncology Therapeutics (BBOT) Price Target According to Analysts?
The average 12-month price target for BridgeBio Oncology Therapeutics is 24.55 USD, with a high estimate of 50 USD and a low estimate of 15 USD. 12 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +601.30% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.